

Supplemental Table 2. Duration, severity and management of identified cases of chronic immune-related adverse

First author	Patient ID	Duration	Ongoing (Y/N)	Grade	ICI held	ICI discontinued	Hospital admission	Steroids	Additional agents	Complications from immunosuppression
Sun ¹	1	119	Y	2		Discontinued ICI	Admission to hospital	oral, IV	Mycophenolate, Infliximab	Steroid induced diabetes, abscess
Di Giacomo ²	2	126	N	2				oral		
Akhtari ³	3	104	N	4		Discontinued ICI	Admission to hospital	oral, IV	Cyclosporine, IVIG	
Harmankaya ⁴	4	730	Y	2		Discontinued ICI		oral		
Manousakis ⁵	5	270	Y	3/4		Discontinued ICI	Admission to hospital	IV	Plasma exchange	
Tissot ⁶	6	150	N	NR		Discontinued ICI				
Dick ⁷	7	1187	Y	3		Discontinued ICI		IV		
Johnson ⁸	8	365	N	2				IV, topical		
	9	1095	N	2						
	10	90	N	2				oral		
Gao ⁹	11	120	N	3	Held ICI			oral, IV	Mycophenolate	
	12	120	N	NR					Cyclosporine	
Jinnur ¹⁰	13	730	Y	NR		Discontinued ICI		oral		
Johncilla ¹¹	14	168	N	NR		Discontinued ICI		oral		
Altman ¹²	15	180	Y	NR		Discontinued ICI		oral		
Yeh ¹³	16	84	Y	NR		Discontinued ICI		intraocular		
Abdallah ¹⁴	17	98	Y	3/4		Discontinued ICI	Admission to hospital	IV	Infliximab	
Papavasileiou ¹⁵	18	120	N	3	Held ICI			oral, IV		
Freeman-Keller ¹⁶	19	129	N	2		Discontinued ICI		oral, IV		
	20	180	N	2		Discontinued ICI		oral		

Khoja ¹⁷	21	90	Y	NR		Discontinued ICI		oral, IV		
Naidoo ¹⁸	22	120	Y	1				oral, topical		
	23	365	Y	1				topical		
Hwang ¹⁹	24	90	N	2		Discontinued ICI		oral	Methotrexate	Pneumonitis
Zimmer ²⁰	25	112	N	4				IV	Plasma exchange	
Beck ²¹	26	196	N	NR		Discontinued ICI		oral		
Bowyer ²²	27	180	N	NR				oral	Mycophenolate, Tacrolimus	
Chia ²³	28	150	N	3		Discontinued ICI		topical		
Cappelli ²⁴	29	90	N	NR	Held ICI			oral		
	30	150	N	NR				topical	Infliximab	
	31	180	N	NR		Discontinued ICI		oral	Adalimumab	
Kimura ²⁵	32	120	N	3/4		Discontinued ICI	Admission to hospital	IV	Plasma exchange, IVIG	
Gouinant ²⁶	33	84	N	2	Held ICI	Discontinued ICI		oral		
Ban-Hoefen ²⁷	34	154	N	NR		Discontinued ICI	Admission to hospital	oral	Cyclosporine	Perirectal abscess
Ascierto ²⁸	35	540	Y	2						
Uemura ²⁹	36	564	N	NR		Discontinued ICI		IV		
Diem ³⁰	37	91	N	2				intraocular		
Wilson ³¹	38	450	N	3				IV	Mycophenolate	Catatonic depression, steroid myopathy
Abe ³²	39	112	Y	3/4		Discontinued ICI	Admission to hospital	oral, IV		Pneumonia
Jung ³³	40	150	N	4		Discontinued ICI	Admission to hospital	oral, IV		Sepsis
Parakh ³⁴	41	210	N	3		Discontinued ICI		oral, topical		
Duffy ³⁵	42	365	N	1				oral, topical		
Spain ³⁶	43	240	N	2		Discontinued		oral, IV	Mycophenolate	

						ICI				
Zarbo ³⁷	44	336	Y	2						
	45	336	Y	NR						
Tetzlaff ³⁸	46	120	N	1				topical		
Bergqvist ³⁹	47	138	N	3		Discontinued ICI		oral	Vedolizumab	
	48	135	N	3		Discontinued ICI		oral	Vedolizumab	
	49	118	N	3		Discontinued ICI		oral	Vedolizumab	
	50	149	N	2		Discontinued ICI		oral	Vedolizumab	
	51	132	N	2		Discontinued ICI		oral	Vedolizumab	
	52	149	N	3		Discontinued ICI		oral	Vedolizumab	
Shiuan ⁴⁰	53	84	N	3		Discontinued ICI		oral		
Spain ⁴¹	54	150	Y	3/4		Discontinued ICI	Admission to hospital	oral		
	55	120	N	3		Discontinued ICI		oral		
	56	147	N	1						
	57	120	N	4		Discontinued ICI	Admission to hospital	IV	IVIG	
Larkin ⁴²	58	180	N	3/4		Discontinued ICI	Admission to hospital	IV	IVIG, Rituximab, Cyclophosphamide	
Kanno ⁴³	59	177	N	2				intraocular		
Uenami ⁴⁴	60	194	N	NR						
Ruiz-Banobre ⁴⁵	61	140	N	1				intraarticular	Sulfasalazine	
Kaunitz ⁴⁶	62	120	N	2		Held ICI		oral		
Kim ⁴⁷	63	90	N	2				oral	Tocilizumab	
Tetzlaff ⁴⁸	64	120	N	NR						
	65	150	N	NR		Discontinued ICI				
Brouwer ⁴⁹	66	270	N	NR		Discontinued		oral		

						ICI				
Hsieh ⁵⁰	67	105	N	3/4		Discontinued ICI	Admission to hospital	oral, IV		
Doherty ⁵¹	68	240	N	4		Discontinued ICI	Admission to hospital	IV	Mycophenolate	Steroid induced diabetes, compression fracture
	69	250	N	3		Discontinued ICI		oral		Compression fracture
	70	116	N	4		Discontinued ICI	Admission to hospital	oral, IV	Mycophenolate	
Balaji ⁵²	71	112	N	2		Discontinued ICI	Admission to hospital	IV		
de Chabot ⁵³	72	140	Y	NR		Discontinued ICI		IV		Cramps
Pföhler ⁵⁴	73	114	N	2		Discontinued ICI		IV		
Benson ⁵⁵	74	90	N	3		Discontinued ICI		oral, IV		
Elosua-Gonzalez ⁵⁶	75	270	N	3/4		Discontinued ICI		oral	Methotrexate	
Alhammad ⁵⁷	76	126	Y	NR		Discontinued ICI		oral, IV		
Kitchlu ⁵⁸	77	120	N	NR		Discontinued ICI		oral		
Rote ⁵⁹	78	330	Y	NR		Discontinued ICI		oral, IV	Methotrexate	
Michot ⁶⁰	79	120	Y	NR		Discontinued ICI		oral		
Narum ⁶¹	80	180	Y	NR		Discontinued ICI	Admission to hospital	IV	Plasma exchange	
Kostine ⁶²	81	168	N	NR				oral	Methotrexate	
	82	168	N	NR				oral	Methotrexate	
Kishi ⁶³	83	210	Y	1		Discontinued ICI				
Kuswanto ⁶⁴	84	365	Y	3/4	Held ICI			oral	Methotrexate	
	85	450	N	2		Discontinued ICI		oral		
	86	180	N	2		Discontinued ICI		oral		

	87	150	Y	2		Discontinued ICI		oral		
McGuire ⁶⁵	88	162	N	4		Discontinued ICI	Admission to hospital	oral, IV	Mycophenolate	
Fellner ⁶⁶	89	90	N	NR	Held ICI			oral		
Kolb ⁶⁷	90	178	Y	3/4		Discontinued ICI	Admission to hospital	oral	Plasma exchange, IVIG	
Luu ⁶⁸	91	120	N	4		Discontinued ICI		oral		
De Martin ⁶⁹	92	365	N	NR		Discontinued ICI		oral, IV	Mycophenolate	
Tetzlaff ⁷⁰	93	180	Y	1		Discontinued ICI				
Matsubara ⁷¹	94	180	Y	3		Discontinued ICI		oral, IV		
Martini ⁷²	95	144	N	3				oral		
	96	381	Y	2				oral		
	97	450	Y	4				oral	Infliximab, IVIG	
	98	444	Y	3				oral	Infliximab, IVIG	
	99	873	Y	2				oral		
Inamo ⁷³	100	1443	Y	3				oral		
	101	180	N	1						
Hid Cadena ⁷⁴	102	180	N	1						
	103	390	Y	NR		Discontinued ICI		oral		
Algaze ⁷⁵	104	100	N	4	Held ICI		Admission to hospital	oral, IV		
Brand ⁷⁶	105	180	N	4				oral, IV		
Mandala ⁷⁷	106	91	N	3		Discontinued ICI		oral, IV		
Badovinac ⁷⁸	107	180	N	3		Discontinued ICI	Admission to hospital	oral, IV		
Lomax ⁷⁹	108	240	Y	3/4		Discontinued ICI		oral		
Takahashi ⁸⁰	109	84	N	2			Admission to hospital	oral	Sulfasalazine	
Tjarks ⁸¹	110	270	Y	NR		Discontinued ICI		oral	Mycophenolate	

Mancone ⁸²	111	180	N	4	Held ICI	Discontinued ICI	Admission to hospital	oral, IV	IVIg	Urinary tract infection
Paolini ⁸³	112	155	Y	NR		Discontinued ICI				
Chen ⁸⁴	113	120	Y	NR				topical		
Derle ⁸⁵	114	120	N	3/4		Discontinued ICI		IV	Plasma exchange, IVIG, Azathioprine	
Tan ⁸⁶	115	210	N	NR		Discontinued ICI	Admission to hospital	oral, IV	Infliximab, Methotrexate	
Narvaez ⁸⁷	116	180	N	NR		Discontinued ICI		oral	Hydroxychloroquine	
Garcia ⁸⁸	117	150	N	NR		Discontinued ICI	Admission to hospital	oral, IV	Infliximab	
	118	84	N	NR		Discontinued ICI		oral		
Sanchez ⁸⁹	119	329	N	NR		Discontinued ICI		oral	Mycophenolate, Infliximab	
Dunn-Pirio ⁹⁰	120	730	N	NR		Discontinued ICI	Admission to hospital	oral	Infliximab	
Burto ⁹¹	121	140	N	3		Discontinued ICI	Admission to hospital	IV	Azathioprine	
Moseley ⁹²	122	480	Y	3		Discontinued ICI			Adalimumab	
Donaldson ⁹³	123	1110	N	NR				oral		
Comont ⁹⁴	124	300	N	NR		Discontinued ICI		oral		
Delaney ⁹⁵	125	91	Y	2				oral		
	126	232	Y	2				oral	IVIg	
	127	322	Y	2				oral	IVIg	
	128	150	Y	2				oral, IV	IVIg, Rituximab	
	129	127	Y	2				oral, IV		
	130	161	N	2				oral	IVIg	
de Jong ⁹⁶	131	360	Y	3		Discontinued ICI	Admission to hospital	oral		
Horisberger ⁹⁷	132	210	N	NR		Discontinued ICI	Admission to hospital	oral, IV, topical	Tocilizumab	
Nakatani ⁹⁸	133	480	Y	3/4		Discontinued ICI	Admission to hospital	oral		

Plaquetent ⁹⁹	134	730	Y	NR						
Cho ¹⁰⁰	135	168	N	3		Discontinued ICI		oral	Azathioprine	
	136	112	N	3/4		Discontinued ICI		oral	IVIg	
	137	140	N	4		Discontinued ICI		oral	IVIg	
	138	84	N	3		Discontinued ICI		oral	IVIg	
	139	126	N	4		Discontinued ICI		oral	Cyclophosphamide	
	140	84	N	4				oral	IVIg	
Nardin ¹⁰¹	141	300	N	NR		Discontinued ICI		oral, IV		
Smith ¹⁰²	142	330	N	NR		Discontinued ICI		intraarticular	Hydroxychloroquine	
	143	390	N	NR		Discontinued ICI		intraarticular		
	144	90	N	NR		Discontinued ICI		intraarticular	Infliximab	
	145	90	Y	NR		Discontinued ICI		oral		
	146	270	Y	NR		Discontinued ICI		oral		
	147	90	Y	NR		Discontinued ICI		oral		
	148	540	N	NR		Discontinued ICI		intraarticular		
	149	450	Y	NR				oral	Sulfasalazine, Hydroxychloroquine	
	150	240	N	NR		Discontinued ICI		oral	Mycophenolate	
Mir ¹⁰³	151	102	N	NR			Admission to hospital	oral	Mycophenolate, Infliximab	
	152	91	N	NR			Admission to hospital	oral	Mycophenolate	
Tauber ¹⁰⁴	153	210	N	3/4		Discontinued ICI		oral, IV	IVIg	
Mamlouk ¹⁰⁵	154	84	Y	3		Discontinued ICI		oral		
Fixsen ¹⁰⁶	155	227	N	3		Discontinued		oral, topical	Cyclosporine	

						ICI				
Lee ¹⁰⁷	156	122	N	NR	Held ICI			oral	Adalimumab	
	157	180	Y	NR				oral		
	158	233	Y	3				oral		
Chana ¹⁰⁸	159	120	N	4		Discontinued ICI	Admission to hospital			
Kim ¹⁰⁹	160	210	Y	2		Discontinued ICI		IV	IVIG	
	161	780	Y	2		Discontinued ICI		oral, topical		
	162	2370	Y	NR		Discontinued ICI		oral, intraocular		
	163	300	Y	NR	Held ICI			oral	IVIG	
	164	450	N	NR		Discontinued ICI		oral	Infliximab	
Leaf ¹¹⁰	165	122	N	2		Discontinued ICI		oral	Rituximab	
	166	300	N	3		Discontinued ICI		oral	IVIG, Rituximab	
	167	160	Y	4		Discontinued ICI		oral, IV		
	168	180	N	3		Discontinued ICI		oral	IVIG, Rituximab, Azathioprine	
	169	138	N	3	Held ICI			oral, IV		
	170	135	N	3	Held ICI			oral		
Porambo ¹¹¹	171	270	Y	NR		Discontinued ICI				
Reed ¹¹²	172	120	Y	3		Discontinued ICI	Admission to hospital	oral, IV		
Lou ¹¹³	173	140	N	NR						
Berger ¹¹⁴	174	98	N	2		Discontinued ICI	Admission to hospital	oral	Cyclophosphamide	
Schoenfeld ¹¹⁵	175	150	N	2		Discontinued ICI	Admission to hospital	oral, IV	Infliximab, IVIG	Hyperglycemia, oral candidiasis
Schwab ¹¹⁶	176	308	N	4	Held ICI		Admission to hospital	oral		
Wouters ¹¹⁷	177	112	N	NR		Discontinued ICI		oral		

Gill ¹¹⁸	178	273	N	3/4		Discontinued ICI	Admission to hospital	oral, IV	Rituximab	
Veronesi ¹¹⁹	179	644	N	2				oral, topical		
Ryuzaki ¹²⁰	180	196	N	3		Discontinued ICI				
Isami ¹²¹	181	84	Y	3/4		Discontinued ICI		oral, IV		
Bezinelli ¹²²	182	322	N	NR		Discontinued ICI	Admission to hospital	oral, IV	Infliximab, IVIG, Rituximab	
Sidiropoulou ¹²³	183	90	N	NR		Discontinued ICI		topical		
Komiya ¹²⁴	184	139	N	2				oral		
	185	88	N	1				oral		
	186	213	Y	3			Admission to hospital	oral, IV		
	187	86	N	2				oral		
	188	95	N	2				oral		
Noda ¹²⁵	189	209	N	2			Admission to hospital	oral, IV	Plasma exchange	
Dubey ¹²⁶	190	180	Y	3/4				oral, IV	Rituximab	
Galli ¹²⁷	191	700	Y	NR				topical		
Yuen ¹²⁸	192	600	Y	3/4		Discontinued ICI	Admission to hospital	IV	IVIG	
Maetani ¹²⁹	193	147	N	3/4				oral, IV		
Shah ¹³⁰	194	150	N	4		Discontinued ICI	Admission to hospital	oral, IV	Mycophenolate	
Blanchard ¹³¹	195	210	Y	NR		Discontinued ICI	Admission to hospital	oral, IV		
Rajan ¹³²	196	122	Y	NR		Discontinued ICI		oral		
Kurokawa ¹³³	197	87	N	3		Discontinued ICI	Admission to hospital	oral		
Martinez-Domenech ¹³⁴	198	180	N	NR				topical		
Thapa ¹³⁵	199	330	N	2		Discontinued ICI		oral	Methotrexate, Sulfasalazine, Hydroxychloroquine	
Reddy ¹³⁶	200	300	Y	NR		Discontinued ICI		oral	Mycophenolate, Tocilizumab	

Sakoh ¹³⁷	201	91	Y	3/4		Discontinued ICI	Admission to hospital	oral	IVIg	
Rkman ¹³⁸	202	780	Y	NR						
Mitropoulou ¹³⁹	203	300	N	NR		Discontinued ICI	Admission to hospital	oral		
Aye ¹⁴⁰	204	150	Y	NR		Discontinued ICI		oral		
Sun ¹⁴¹	205	84	N	NR		Discontinued ICI		oral		
	206	120	Y	NR	Held ICI			oral, IV		
Ahem ¹⁴²	207					Discontinued ICI	Admission to hospital	IV	Plasma exchange, IVIG	
Olson ¹⁴³	208	120	N	3		Discontinued ICI	Admission to hospital	oral, IV	Mycophenolate, Cyclosporine	
Cordes ¹⁴⁴	209	600	N	3/4		Discontinued ICI		oral, IV	Mycophenolate	
Haddad ¹⁴⁵	210	365	Y	NR		Discontinued ICI				
Thomas ¹⁴⁶	211	254	Y	NR			Admission to hospital	oral, IV		
Irifuku ¹⁴⁷	212	136	N	2	Held ICI		Admission to hospital	oral, IV		
Malek ¹⁴⁸	213	150	N	NR		Discontinued ICI	Admission to hospital	oral, IV	Mycophenolate	Necrotizing soft tissue infection
Guo ¹⁴⁹	214	180	N	3		Discontinued ICI		oral, IV	Mycophenolate	
Miyahara ¹⁵⁰	215	120	N	3		Discontinued ICI		oral	Infliximab	
	216	120	Y	3		Discontinued ICI		oral		
Ok ¹⁵¹	217	180	N	1	Held ICI					
Chan ¹⁵²	218	1095	N	NR		Discontinued ICI		oral	Methotrexate	
	219	365	Y	NR		Discontinued ICI		oral	Methotrexate	
Taillefer ¹⁵³	220	112	Y	3/4		Discontinued ICI	Admission to hospital	oral, IV		
Xu ¹⁵⁴	221	168	Y	1						
Subedi ¹⁵⁵	222	126	N	3/4		Discontinued ICI		oral		

	223	560	N	3/4				intraarticular		
	224	112	Y	3/4	Held ICI			oral		
	225	168	N	3/4		Discontinued ICI		oral	Methotrexate	
	226	91	N	3/4						
Mizuno ¹⁵⁵	227	98	N	NR		Discontinued ICI	Admission to hospital	oral		Sepsis
Rossi ¹⁵⁷	228	210	N	1				topical		
Robert ¹⁵⁸	229	317	N	3/4		Discontinued ICI	Admission to hospital	oral, IV		
	230	180	N	3/4		Discontinued ICI	Admission to hospital	oral, IV		
Xing ¹⁵⁹	231	84	Y	4	Held ICI	Discontinued ICI	Admission to hospital	IV	Plasma exchange, IVIG	
Terashima ¹⁶⁰	232	240	N	NR		Discontinued ICI	Admission to hospital	oral		
Daoussis ¹⁶¹	233	180	N	NR				oral		
	234	180	N	NR				oral		
	235	180	N	NR				oral		
	236	180	N	NR				oral		
	237	180	N	NR				oral		
Liu ¹⁶²	238	195	N	3	Held ICI		Admission to hospital	oral, IV		
Marques-Piubelli ¹⁶³	239	240	Y	NR				topical		
Ogawa ¹⁶⁴	240	84	N	1				oral, IV		
Von Itzstein ¹⁶⁵	241	127	N	4			Admission to hospital	oral, IV	IVIG	
Leaver ¹⁶⁶	242	105	N	2		Discontinued ICI	Admission to hospital	oral	Mycophenolate	
Samejima ¹⁶⁷	243	120	N	NR		Discontinued ICI	Admission to hospital			Orthostatic hypotension
Nowosielski ¹⁶⁸	244	280	Y	1		Discontinued ICI		IV	Methotrexate, Rituximab	Steroid-induced diabetes
Tanabe ¹⁶⁹	245	112	Y	1		Discontinued ICI		oral		
Ueki ¹⁷⁰	246	493	Y	4		Discontinued ICI	Admission to hospital			

Kambayashi ¹⁷¹	247	87	Y	2			Admission to hospital	oral, IV		
Rizell ¹⁷²	248	330	N	3				oral	Mycophenolate	
Zarkavelis ¹⁷³	249	150	N	3/4		Discontinued ICI		oral	IVIg	
Hendrix ¹⁷⁴	250	120	N	4		Discontinued ICI		IV	IVIg	
Terriera ¹⁷⁵	251	180	N	4		Discontinued ICI	Admission to hospital		Cyclophosphamide	
Murray-Brown ¹⁷⁶	252	540	Y	3				oral, intraarticular	Infliximab, Methotrexate, Hydroxychloroquine	
Parikh ¹⁷⁷	253	210	N	NR		Discontinued ICI				
Osaki ¹⁷⁸	254	180	N	1		Discontinued ICI		IV	Tacrolimus, IVIg	
Bhattacharyya ¹⁷⁹	255	194	N	NR		Discontinued ICI		topical	Rituximab	
Uner ¹⁸⁰	256	90	Y	1		Discontinued ICI	Admission to hospital	oral, IV		
Todo ¹⁸¹	257	321	N	3/4		Discontinued ICI	Admission to hospital	oral		
Ueki ¹⁸²	258	180	N	1		Discontinued ICI				
Pundole ¹⁸³	259	120	N	NR				oral		
McClure ¹⁸⁴	260	126	N	3		Discontinued ICI		oral		
Iyer ¹⁸⁵	261	600	Y	4		Discontinued ICI	Admission to hospital	IV	Plasma exchange, IVIg	
Uchio ¹⁸⁶	262	572	N	2	Held ICI					
Wong ¹⁸⁷	263	140	N	3/4		Discontinued ICI	Admission to hospital	oral	IVIg, Rituximab	
Lin ¹⁸⁸	264	240	N	1	Held ICI					
Kullberg ¹⁸⁹	265	180	Y	NR		Discontinued ICI		oral		
Tanaka ¹⁹⁰	266	145	N	3		Discontinued ICI	Admission to hospital	oral, IV	Azathioprine	
Patel ¹⁹¹	267	90	N	3		Discontinued ICI		oral, IV		
	268	120	N	2		Discontinued ICI		oral	Mycophenolate	

	269	90	N	3		Discontinued ICI		oral		
Ziogas ¹⁹²	270	133	N	4		Discontinued ICI	Admission to hospital	oral, IV	Mycophenolate, Tacrolimus	Thrombocytopenia
Siciliano ¹⁹⁴	271	280	Y	3	Held ICI			oral, IV	PDE-4 inhibitor	
Ueki ¹⁹⁴	272	199	N	NR		Discontinued ICI		oral		
Yoshikawa ¹⁹⁵	273	133	N	1				oral	Mycophenolate	
Onishi ¹⁹⁶	274	111	Y	3	Held ICI			oral		
Peng ¹⁹⁷	275	210	N	NR		Discontinued ICI		oral, IV, topical		
Giaccone ¹⁹⁸	276	300	N	NR	Held ICI			oral, IV		
	277	1320	Y	NR		Discontinued ICI		oral	IVIg	
Paparoopa ¹⁹⁹	278	270	N	2				oral, topical	Infliximab	
Kanaoka ²⁰⁰	279	265	N	2		Discontinued ICI		oral	Azathioprine	
Wang ²⁰¹	280	540	Y	1	Held ICI					
Vogrig ²⁰²	281	300	N	NR		Discontinued ICI		IV		
Rosner ²⁰³	282	210	N	NR						
Liu ²⁰⁴	283	365	N	1		Discontinued ICI	Admission to hospital	IV	IVIg	
Scanvion ²⁰⁵	284	105	N	2						
	285	138	N	2	Held ICI					
	286	259	N	1		Discontinued ICI				
	287	182	N	1						
	288	182	N	1	Held ICI					
	289	151	N	2		Discontinued ICI		oral		
	290	917	N	2						
	291	133	N	NR	Held ICI					
	292	205	N	1	Held ICI			oral		
	293	182	N	NR						
294	172	N	2	Held ICI						

	295	300	N	NR	Held ICI					
Beninato ²⁰⁶	296	86	N	NR		Discontinued ICI		oral		
Okada ²⁰⁷	297	252	Y	3/4		Discontinued ICI	Admission to hospital	oral, IV	IVIg	
Bui ²⁰⁸	298	180		1				topical	Hydroxychloroquine	
Bejarano ²⁰⁹	299	210	Y	2		Discontinued ICI		oral		
Gallo ²¹⁰	300	365	Y	3		Discontinued ICI	Admission to hospital	oral, IV		
Godar ²¹¹	301	84	N	3/4		Discontinued ICI	Admission to hospital	oral	Cyclosporine	
Ruini ²¹²	302	900	N	3		Discontinued ICI	Admission to hospital	oral, IV	Tacrolimus	
	303	720	Y	1			Admission to hospital	IV	Mycophenolate, Sirolimus	
Huntley ²¹³	304	180	N	2		Discontinued ICI		oral		Aggressive behaviors
	305	810	N	2	Held ICI			oral		
Koch ²¹⁴	306	84	Y	2				oral		
Suyama ²¹⁵	307	138	N	4		Discontinued ICI		oral		
Duong ²¹⁶	308	180	N	3				oral, IV	IVIg	
Honma ²¹⁷	309	90	N	3			Admission to hospital	oral, IV		
Villarreal ²¹⁸	310	180	N	3/4		Discontinued ICI		Steroids- oral		
Murray ²¹⁹	311	140	N	3/4		Discontinued ICI			Methotrexate, Sulfasalazine, Tofacitinib	
Dombides ²²⁰	312	210	N	3		Discontinued ICI	Admission to hospital	oral, IV		
Shahzad ²²¹	313	180	N	NR						
Kim ²²²	314	120	N	3/4		Discontinued ICI		oral	Methotrexate	Gastrointestinal symptoms, right anterior uveitis
Maillard ²²³	315	504	N	1						
Stürmer ²²⁴	316	180	N	2	Held ICI			oral		
	317	300	N	2		Discontinued				

						ICI				
Ogawa ²²⁵	318	120	N	1		Discontinued ICI		oral, IV		Esophageal candida
Janssen ²²⁶	319	259	N	2				IV	IVIG	
Williams ²²⁷	320	180	N	2		Discontinued ICI	Admission to hospital	oral, IV	Mycophenolate, IVIG	
Lin ²²⁸	321	207	N	1						
	322	90	N	3	Held ICI			oral		
	323	265	N	2	Held ICI					

Abbreviations: Y, yes, N, no, NR, not reported, ICI, immune checkpoint inhibitor, irAE, immune-related adverse event, IV, intravenous, IVIG, Intravenous immune globulin, PDE-4, phosphodiesterase-4